Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
- Status
- TERMINATED
- Phase
- PHASE1
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
- Status
- COMPLETED
- Phase
- PHASE1
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
- Status
- TERMINATED
- Phase
- PHASE2
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
- Status
- COMPLETED
- Phase
- PHASE2
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
- Status
- TERMINATED
- Phase
- PHASE2
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2